Видео ютуба по тегу Medicines: Cabazitaxel

Dr. Sweeney on the Optimal Use of Cabazitaxel
Dr. Sweeney on the Optimal Use of Cabazitaxel
Cabazitaxel Improves rPFS in Patients with mCRPC
Cabazitaxel Improves rPFS in Patients with mCRPC
Cabazitaxel safe and effective in mCRPC
Cabazitaxel safe and effective in mCRPC
Treatment sequencing in mCRPC: cabazitaxel vs. abiraterone or enzalutamide
Treatment sequencing in mCRPC: cabazitaxel vs. abiraterone or enzalutamide
CARD Trial: Cabazitaxel After AR-Targeted Therapy in mCSPC
CARD Trial: Cabazitaxel After AR-Targeted Therapy in mCSPC
TheraP: cabazitaxel versus 177Lu-PSMA-617 for mCRPC
TheraP: cabazitaxel versus 177Lu-PSMA-617 for mCRPC
JEVTANA® (cabazitaxel) Mechanism of Action
JEVTANA® (cabazitaxel) Mechanism of Action
Cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer
Cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer
Treatment Adherence to Inform Treatment Efficacy
Treatment Adherence to Inform Treatment Efficacy
Cabazitaxel Impacts Sequencing Strategies in Prostate Cancer
Cabazitaxel Impacts Sequencing Strategies in Prostate Cancer
TheraP: LuPSMA versus cabazitaxel for prostate cancer
TheraP: LuPSMA versus cabazitaxel for prostate cancer
Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in mPC
Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in mPC
Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer
Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer
Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC
Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC
Treatment Options in Metastatic Prostate Cancer
Treatment Options in Metastatic Prostate Cancer
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docet...
LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docet...
3-weekly cabazitaxel not ruled out as first-line option for metastatic breast cancer | Amit Bahl
3-weekly cabazitaxel not ruled out as first-line option for metastatic breast cancer | Amit Bahl
Researcher comment: Cabazitaxel a new third-line option in mCRPC | Ronald de Wit
Researcher comment: Cabazitaxel a new third-line option in mCRPC | Ronald de Wit
Cabazitaxel Use in Metastatic Prostate Cancer
Cabazitaxel Use in Metastatic Prostate Cancer
Dr. Grivas on Potential Combinations With Cabazitaxel in Prostate Cancer
Dr. Grivas on Potential Combinations With Cabazitaxel in Prostate Cancer